Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,511.45
(
2.64%
)
US TECH 100
23,032.00
(
3.14%
)
Dow Jones
46,261.89
(
2.31%
)
Brent Oil
104.26
(
-3.97%
)
Bitcoin
67,812.99
(
1.67%
)
News Focus
News Focus
Post# of 257320
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122828
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 243169

Wednesday, 05/17/2023 11:54:01 AM

Wednesday, May 17, 2023 11:54:01 AM

Post# of 257320
ICPT -21% on_FDA_briefing_doc_for Ocaliva/NASH adcomm:

https://finance.yahoo.com/news/us-fda-staff-flag-liver-131347282.html

I’ve posted many times that Ocaliva is simply a bad drug for NASH that should not be approved for this indication—e.g. #msg-169362197 and #msg-170082971. No amount of data reanalysis will change this.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today